Name: | Description: | Size: | Format: | |
---|---|---|---|---|
3.74 MB | Adobe PDF |
Advisor(s)
Abstract(s)
BACKGROUND: Leukemia inhibitory factor (LIF) and interleukin-6 (IL-6)
are members of the family of the glycoprotein 130 (gp130)-type
cytokines. These cytokines share gp130 as a common signal transducer,
which explains why they show some functional redundancy. Recently, it
was demonstrated that IL-6 promotes fetal lung branching.
Additionally, LIF has been implicated in developmental processes of
some branching organs. Thus, in this study LIF expression pattern and
its effects on fetal rat lung morphogenesis were assessed.
METHODOLOGY/PRINCIPAL FINDINGS: LIF and its subunit receptor LIFRα
expression levels were evaluated by immunohistochemistry and western
blot in fetal rat lungs of different gestational ages, ranging from
13.5 to 21.5 days post-conception. Throughout all gestational ages
studied, LIF was constitutively expressed in pulmonary epithelium,
whereas LIFRα was first mainly expressed in the mesenchyme, but after
pseudoglandular stage it was also observed in epithelial cells. These
results point to a LIF epithelium-mesenchyme cross-talk, which is
known to be important for lung branching process. Regarding functional
studies, fetal lung explants were cultured with increasing doses of
LIF or LIF neutralizing antibodies during 4 days. MAPK, AKT, and STAT3
phosphorylation in the treated lung explants was analyzed. LIF
supplementation significantly inhibited lung growth in spite of an
increase in p44/42 phosphorylation. On the other hand, LIF inhibition
significantly stimulated lung growth via p38 and Akt pathways.
CONCLUSIONS/SIGNIFICANCE: The present study describes that LIF and its
subunit receptor LIFRα are constitutively expressed during fetal lung
development and that they have an inhibitory physiological role on
fetal lung
Description
Keywords
Factor Inibidor de Leucemia Atraso de Crescimento Fetal Pulmão Ratos
Citation
PLoS One. 2012;7(1):e30517.